WebApr 12, 2024 · In 2024, Regeneron collaborated with Alnylam Pharmaceuticals, Inc. to discover RNA interference ("RNAi") therapeutics for NASH and potentially other related diseases, as well as to research, co ... WebApr 7, 2024 · Regeneron Pharmaceuticals Inc’s trailing 12-month revenue is $12.2 billion with a 35.6% profit margin. Year-over-year quarterly sales growth most recently was -31.0%. Analysts expect adjusted earnings to reach $41.359 per share for the current fiscal year. Regeneron Pharmaceuticals Inc does not currently pay a dividend.
Regeneron Pharmaceuticals Inc REGN Stock Quote
WebApr 10, 2024 · Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, its unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in … WebApr 11, 2024 · Regeneron Announces Investor Conference Presentations. TARRYTOWN, N.Y., April 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: BofA Securities 2024 Health Care Conference at 1:40 p.m. PT (4:40 p.m. ET) on Tuesday, May 9, 2024. find last name middle name first name
Regeneron Pharmaceuticals, Inc. (REGN) - Yahoo Finance
WebView the latest Regeneron Pharmaceuticals Inc. (REGN) stock price, news, historical charts, analyst ratings and financial information from WSJ. WebApr 6, 2024 · On Thursday, Regeneron Pharmaceuticals Inc (REGN:NSQ) closed at 828.73, -1.05% below its 52-week high of 837.55, set on Apr 05, 2024. Data delayed at least 15 minutes, as of Apr 06 2024 21:00 BST. WebStock analysis for Regeneron Pharmaceuticals Inc (REGN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. find last non blank cell in a row